Alimera Sciences Reports Fourth Quarter and Full Year 2017 Financial Results

Pharmaceutical Investing

Alimera Sciences (Nasdaq: ALIM) a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced financial results for the three months and full-year ended December 31, 2017. Alimera will host a conference call on March 1, 2018 at 9:00 a.m. ET to discuss these results. As quoted in the …

As quoted in the press release:

“In 2017, pursuant to our plans, we significantly reduced both our GAAP net loss and our Adjusted EBITDA net loss by 34% and 61%, respectively. Physician demand in the U.S. for ILUVIEN has continued to grow throughout the fourth quarter and into 2018, and we have expanded our sales presence to leverage this opportunity moving forward,” said Dan Myers, Alimera’s Chief Executive Officer.

Click here to read the full press release.

conference call financial results iluvien ophthalmic Pharmaceutical Investing